Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find out if decitabine, given with or without
valproic acid, can help to control AML or MDS. The safety of both treatments will also be
studied.